London Stock Exchange welcomes Belluscura plc to AIM

London Stock Exchange today welcomes Belluscura plc (“Belluscura” or the “Company”), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, to celebrate the listing of the Company's public shares onto AIM, under the ticker "BELL".

Belluscura focuses on novel oxygen-based treatment platforms that can be adapted and applied in a wide range of markets beyond those traditionally applicable to a single product or product line. Its range of portable products will be lighter, more adaptable and have higher O₂ capacity by weight than existing oxygen enrichment products in their respective class. Whilst potentially useful for recovering COVID patients, it has a wide range of use for sufferers of pneumonia and COPD (i.e. asthma, emphysema and chronic bronchitis) and other respiratory illnesses. In March 2021, it received 510(k) clearance from the US Food & Drug Administration (FDA) for its X-PLO₂R range of oxygen concentrators, which will be launched in 2021.

The company has successfully raised £17.5 million from the placing and subscription, and will have a market capitalisation of £50.96 million based on the issue price of 45p.

The Company has a registered office in the UK. Its subsidiary, Belluscura LLC, is based in Plano, Texas, USA. The USA is the Company’s main country of operation.

Robert Rauker, CEO of Belluscura, said: “We are delighted to announce our admission to AIM. These additional funds will allow us to accelerate our sales effort and the commercial roll-out of the first of our portfolio of oxygen concentrators under development. Our patented oxygen enrichment technology is designed to positively impact millions of people across the globe suffering from serious respiratory diseases.

“Our debut on AIM sees us well-positioned for commercial growth and well-financed to support the launch of our FDA cleared X-PLO₂R portable oxygen concentrator as well as advancing the other products within our portfolio to commercial launch.

“We look forward to welcoming support from investors for our portable oxygen enrichment technology, which will make a huge difference to people who need supplemental oxygen to enjoy a more active lifestyle at a reduced cost.”

Quick facts

Market: AIM
Instrument market cap (£m)
Listing/Admission to trading
28 May 2021
Looking for new and recent issues?

More recent

London Stock Exchange welcomes Graft Polymer Plc to the Main Market

The London Stock Exchange today welcomes Graft Polymer (UK) PLC, a business focused on the development of polymer modification, bio/food supplements and drug delivery systems, to the Main Market, trading under the ticker symbol “GPL”.

Graft Polymer is an early-stage company with a state-of-the-art polymer research and development, manufa

Learn more
London Stock Exchange welcomes Genflow Biosciences Plc to the Main Market

London Stock Exchange today welcomes Genflow Biosciences Plc, a UK-based biotechnology company focused on longevity and the development of therapies to counteract the effects of aging and diseases associated with advanced age, to the Standard Listing Segment of the Main Market, under the ticker symbol "GENF".

Genflow Biosciences opened th

Learn more
London Stock Exchange welcomes East Star Resources Plc and their readmission to the Main Market

London Stock Exchange welcomes the readmission of East Star Resources, a company focused on the discovery and development of gold, copper, and base metals in Kazakhstan, to the Main Market under the ticker “EST”. The company raised gross proceeds of £3.1 million via a placing and subscription of 62,000,000 shares at £0.05 per share, delivering a ma

Learn more
London Stock Exchange celebrates FTSE Russell’s index partnership with Abu Dhabi Securities Exchange

Today, London Stock Exchange markets were opened by Abu Dhabi Securities Exchange and FTSE Russell to mark their partnership and the launch of the FTSE ADX Index Series.

FTSE ADX General Index FTSE ADX Sector Indexes FTSE Russell provides daily index calculations on the ADX General Index FTSE ADX General Index replaces the ADX General Index FTSE Russ

Learn more